CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) — Biogen Inc. BIIB today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations, effective April 10, 2023. Mr. Triano will report to Michael McDonnell, executive vice president and chief financial officer.

“Chuck will bring invaluable industry knowledge and a strong network of relationships to Biogen, and I am pleased to welcome him to our leadership team,” said Michael McDonnell, executive vice president and chief financial officer. “His wealth of experience working with corporate leaders during times of rapid growth and transition will enhance our ongoing efforts to educate investors about our go-forward strategy as we work on our journey to sustained growth.”

Mr. Triano brings over 35 years of finance experience to this role, having held executive positions at leading biotechnology and pharmaceutical companies for the past two decades, most recently as Chief Financial Officer for Xalud Therapeutics.

Prior to joining Xalud Therapeutics, Mr. Triano was Senior Vice President of Investor Relations at Pfizer for over a decade, where he was responsible for all global investor relations functions and operational planning and analysis. Previously, he was Vice President of Investor Relations at Forest Laboratories, where he initiated the company’s first formal investor relations and corporate communications program. He was also a Managing Director at The Carson Group, a financial information organization specializing in global shareholder research and capital markets information. He holds a bachelor’s degree from the University of Connecticut.

Mike Hencke, Executive Director, Investor Relations, and the Investor Relations team will report to Mr. Triano.

About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered several breakthrough innovations, including a broad portfolio of drugs to treat multiple…